Loading...
XJPX
2183
Market cap43mUSD
Dec 05, Last price  
302.00JPY
1D
0.00%
1Q
-10.39%
Jan 2017
-76.01%
IPO
-0.98%
Name

Linical Co Ltd

Chart & Performance

D1W1MN
XJPX:2183 chart
P/E
—
P/S
0.65
EPS
—
Div Yield, %
4.97%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.93%
Revenues
10.44b
-15.20%
1,273,038,0002,036,005,0002,404,340,0002,512,015,0003,110,236,0003,599,236,0003,721,832,0004,872,041,0007,666,824,0008,355,754,0009,113,157,00011,313,468,00010,935,241,00010,279,314,00011,555,088,00012,516,998,00012,307,870,00010,437,032,000
Net income
-539m
L
296,584,000300,478,000273,611,000147,885,000424,199,000616,787,000449,185,000437,139,0001,330,970,0001,447,513,0001,295,994,000568,455,000482,990,000539,968,000790,487,0001,004,368,000338,266,000-539,102,000
CFO
595m
-44.11%
273,153,000161,380,000351,537,000-108,007,000613,430,000909,215,000249,212,000690,010,0001,817,153,0002,291,683,0001,360,117,000-796,810,0001,192,344,00023,610,0001,631,794,0001,839,628,0001,065,469,000595,475,000
Dividend
Mar 30, 202616 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
URL
https://www.linical.co.jp/
IPO date
Oct 27, 2008
Employees
759
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT